<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02366676</url>
  </required_header>
  <id_info>
    <org_study_id>2013-07-170</org_study_id>
    <nct_id>NCT02366676</nct_id>
  </id_info>
  <brief_title>Efficacy of IARULIL® in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract</brief_title>
  <official_title>Efficacy of Combined Intravesical Therapy With Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract: a Multicenter, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of Combined Intravesical Therapy With
      Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to
      Escherichia Coli Extract
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy of combined intravesical therapy with
      hyaluronic acid and chondroitin sulphate(IARULIL®) in the treatment of recurrent cystitis
      refractory to oral Escherichia Coli extract(Uro-Vaxom®) and the change of urinary tract
      infection symptoms after intravesical instillation treatment with IARULIL®.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">October 30, 2019</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of recurrence for recurrent cystitis</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time interval of cystitis</measure>
    <time_frame>12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The score change of UTI symptom Assessment questionnaire(UTISA)</measure>
    <time_frame>12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Respone assessment(GRA) score assessment</measure>
    <time_frame>12 month after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety evaluation Safety evaluation</measure>
    <time_frame>12 month after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Recurrent Cystitis</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Intervention: combined intravesical therapy with hyaluronic acid and chondroitin sulphate(IALURIL®) ( 1st month: once a week, 2nd~5th month:once a month)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hyaluronic acid and chondroitin sulphate</intervention_name>
    <description>IALURIL Intravesical instillation with cystoscope ( 1st month: once a week, 2nd~5th month:once a month)</description>
    <arm_group_label>treatment group</arm_group_label>
    <other_name>IALURIL®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. female patients aged between 20 and 80 years

          2. Patients diagnosed with recurrent cystitis and treated with Escherichia Coli Extract

          3. Patients with Refractory to Escherichia Coli Extract treatment

        Exclusion Criteria:

          1. child-bearing potential, pregnant or nursing women.

          2. Residual urine volume &gt;100ml

          3. genitourinary tuberculosis or cancer / anatomical abnomality of genitourinary tract /
             neurologic abnormality of low urinary tract.

          4. history of treatment for acute cystitis within 2weeks.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu-Sung Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul,</city>
        <zip>130-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>November 28, 2019</last_update_submitted>
  <last_update_submitted_qc>November 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>KYU-SUNG LEE</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Recurrent cystitis</keyword>
  <keyword>hyaluronic acid</keyword>
  <keyword>chondroitin sulphate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

